Literature DB >> 18191815

Lobeline effects on tonic and methamphetamine-induced dopamine release.

Clare J Wilhelm1, Robert A Johnson, Amy J Eshleman, Aaron Janowsky.   

Abstract

The mechanisms of interaction between lobeline and the dopamine transporter (DAT) or the vesicular monoamine transporter (VMAT-2) are not clear. The goal of this study was to elucidate the effects of lobeline on these transporters in a cell system co-expressing the DAT and VMAT-2. Lobeline caused release of [(3)H]dopamine to a similar extent as reserpine (VMAT-2 inhibitor), but was less efficacious than methamphetamine or dopamine. Additionally, lobeline decreased the [(3)H]dopamine-releasing effects of methamphetamine, unlike reserpine which increased release by methamphetamine. These results suggest that lobeline has unique properties at the DAT and VMAT-2 which may make it useful as a pharmacotherapeutic to treat methamphetamine abuse.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18191815      PMCID: PMC2435375          DOI: 10.1016/j.bcp.2007.11.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

Review 1.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

2.  Lobeline inhibits the neurochemical and behavioral effects of amphetamine.

Authors:  D K Miller; P A Crooks; L Teng; J M Witkin; P Munzar; S R Goldberg; J B Acri; L P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

3.  Lobeline does not serve as a reinforcer in rats.

Authors:  Steven B Harrod; Linda P Dwoskin; Thomas A Green; Brenda J Gehrke; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2002-11-30       Impact factor: 4.530

4.  Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.

Authors:  Clare J Wilhelm; Robert A Johnson; Paul G Lysko; Amy J Eshleman; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2004-04-21       Impact factor: 4.030

Review 5.  Approaches to the development of medications for the treatment of methamphetamine dependence.

Authors:  Frank J Vocci; Nathan M Appel
Journal:  Addiction       Date:  2007-04       Impact factor: 6.526

6.  Presynaptic modulation of the release of dopamine from striatal synaptosomes: differences in the effects of high K+ stimulation, methamphetamine and nicotinic drugs.

Authors:  Y Takano; Y Sakurai; Y Kohjimoto; K Honda; H O Kamiya
Journal:  Brain Res       Date:  1983-11-21       Impact factor: 3.252

7.  Non-neurogenic mechanism for reserpine-induced release of catecholamines from the adrenal medulla of neonatal rats: possible modulation by opiate receptors.

Authors:  C J Chantry; F J Seidler; T A Slotkin
Journal:  Neuroscience       Date:  1982-03       Impact factor: 3.590

8.  Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugs.

Authors:  Y Sakurai; Y Takano; Y Kohjimoto; K Honda; H O Kamiya
Journal:  Brain Res       Date:  1982-06-17       Impact factor: 3.252

9.  Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.

Authors:  Dennis K Miller; Peter A Crooks; Guangrong Zheng; Vladimir P Grinevich; Seth D Norrholm; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2004-04-30       Impact factor: 4.030

10.  Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.

Authors:  John W Haycock; Laurence Becker; Lee Ang; Yoshiaki Furukawa; Oleh Hornykiewicz; Stephen J Kish
Journal:  J Neurochem       Date:  2003-11       Impact factor: 5.372

View more
  17 in total

1.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

Review 2.  Cholinergic functioning in stimulant addiction: implications for medications development.

Authors:  Mehmet Sofuoglu; Marc Mooney
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

Review 3.  Novel medications to treat addictive disorders.

Authors:  Iván D Montoya; Frank Vocci
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

Review 4.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

5.  New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.

Authors:  Na-Ra Lee; Guangrong Zheng; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  AAPS J       Date:  2018-02-09       Impact factor: 4.009

6.  The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-04       Impact factor: 3.584

7.  Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.

Authors:  A C Meyer; D B Horton; N M Neugebauer; T E Wooters; J R Nickell; L P Dwoskin; M T Bardo
Journal:  Neuropharmacology       Date:  2011-06-12       Impact factor: 5.250

8.  Development of serotonin transporter reuptake inhibition assays using JAR cells.

Authors:  Ann M Decker; Bruce E Blough
Journal:  J Pharmacol Toxicol Methods       Date:  2018-03-16       Impact factor: 1.950

9.  Modulation of aggressive behavior in mice by nicotinic receptor subtypes.

Authors:  Alan S Lewis; Yann S Mineur; Philip H Smith; Emma L M Cahuzac; Marina R Picciotto
Journal:  Biochem Pharmacol       Date:  2015-07-23       Impact factor: 5.858

10.  Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.

Authors:  Andrew C Meyer; Nichole M Neugebauer; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  J Neurochem       Date:  2013-08-20       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.